Vistagen therapeutics

In therapeutic settings, understanding the dynam

VistaGen is committed to developing and commercializing multiple new generation medications that go beyond the standard of care in large markets for treatment ...Sep 8, 2022 ... VistaGen Therapeutics will continue its phase 3 social anxiety trial of its nose spray after a pause post the failure of a similar ...

Did you know?

October 14, 2021 08:00 ET | Source: VistaGen Therapeutics, Inc. Follow. Study Launches Phase 2A Clinical Program Designed to Explore PH94B’s Potential in Multiple Additional …Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for treating anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes six clinical-stage product candidates, including five investigational agents belonging to a new ...VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities. ... Vistagen is developing an innovative pipeline of neuroscience medications with ...... VistaGen Therapeutics. 1. How has your career led you to VistaGen, and why did you choose to move into CNS biopharmaceuticals? I am passionate about ...Apr 25, 2024 · Vistagen’s sixth investigational candidate is an oral prodrug with potential to modulate NMDA receptor activity. At Vistagen, we are passionate about delivering differentiated treatments that set new standards of care for people living with anxiety, depression, and other neurological disorders. Aug 21, 2023 · Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available ... The latest price target for . Vistagen Therapeutics (NASDAQ: VTGN) was reported by Jefferies on Thursday, December 7, 2023.The analyst firm set a price target for 15.00 expecting VTGN to rise to ...2 days ago · Vistagen Therapeutics, Inc is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Vistagen Therapeutics, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vistagen Therapeutics, Inc or its management. A beaten down micro-cap biotech company, Vistagen Therapeutics Inc., notched its best day ever, surging by as many as four digits after its experimental nasal spray for social anxiety disorder hit ...About VistaGen VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's drug candidates has a differentiated potential mechanism of action, has …Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for treating anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes six clinical-stage product candidates, including five investigational agents belonging to a new ...`Net Income (Loss) Available to Common Stockholders, Basic` reported by Vistagen Therapeutics, Inc. to the SEC. Formalu Locations. United States. Browse By State …Discover real-time Vistagen Therapeutics, Inc. Common Stock (VTGN) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. Vistagen’s clinical-stage candidates are targeting multiple forms of anxiety and depression.Nov 15, 2022 · Earnings Estimate Revisions for VistaGen Therapeutics, Inc. This company is expected to earn -$0.28 per share for the fiscal year ending March 2023, which represents a year-over-year change of -12%.

Feb 28, 2023 ... Expert Career Advice ... Glassdoor gives you an inside look at what it's like to work at VistaGen Therapeutics, including salaries, reviews, ...Vistagen’s sixth investigational candidate is an oral prodrug with potential to modulate NMDA receptor activity. At Vistagen, we are passionate about delivering differentiated treatments that set new standards of care for people living with anxiety, depression, and other neurological disorders.Aug 11, 2022 · VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2022 2022 (unaudited) Senior Vice President, Translational Neuroscience. Dr. Monti joined Vistagen as Vice President, Translational Medicine in December 2020. Prior to joining Vistagen, Dr. Monti served in multiple leadership roles at Pherin Pharmaceuticals since its founding in 1991, including President and CEO from July 2018 through November 2020, Executive Vice ...VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care ...

A free inside look at VistaGen Therapeutics salary trends based on 4 salaries wages for 4 jobs at VistaGen Therapeutics. Salaries posted anonymously by ...Maggie FitzPatrick. Maggie FitzPatrick joined our Board of Directors in July 2021 and has served as Chair since October 2023. Ms. FitzPatrick is a globally recognized corporate affairs executive who has been honored with several prestigious awards, including the Washington Business Journal’s C-Suite Executive of the Year Class (2019), PR Week ...VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) March 31, March 31, 2022. 2021 ASSETS: Current assets:…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Apr 22, 2024 ... VistaGen Therapeutics Inc'. Possible cause: As people age, they may find it more difficult to get in and out of a traditio.

Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for treating anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes six clinical-stage product candidates, including five investigational agents belonging to a new ...As we age, it’s important to keep our minds sharp and engaged. One way to do this is by participating in crossword puzzles. Not only are they a fun and enjoyable activity, but they...

SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Jun. 2, 2022-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today …15 Dec 2022 ... Live stream the Vistagen Therapeutics, Inc (Nasdaq: VTGN) presentation from the December 15, 2022 KCSA Mental Health Virtual Investor ...Gardening is not only a hobby but also a therapeutic activity that allows individuals to connect with nature and create a beautiful outdoor space. To ensure that your garden thrive...

Itruvone is an odorless synthetic investigational neur AV-101 VistaGen Therapeutics major depressive disorder (Fast Track), Phase II (NMDA receptor glycine B antagonist) South San Francisco, CA major depressive disorder … May 4, 2021 · VistaGen Therapeutics is a bioVistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical c Itruvone (PH10) Publications. Monti, L., Smith, M., & Hanover, R. (2022). PH10: A new intranasal neuroactive steroid with rapid onset of antidepressant effect but a mechanism of action different from GABA‐A allosteric modulator antidepressants. Anxiety and Depression Association of Am. March 19, 2022. A beaten down micro-cap biotech company, Vistagen Therapeutic Vistagen Therapeutics had a negative return on equity of 72.10% and a negative net margin of 3,073.51%. The firm had revenue of $0.41 million for the quarter, … Vistagen (Nasdaq: VTGN) is a late clinical-stage bSep 30, 2023 · Vistagen (Nasdaq: VTGN) is a late clinical-stage bioVISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEE Get the latest Vistagen Therapeutics Inc (VTGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. A beaten down micro-cap biotech company, Vistagen Therapeutics I Who is Vistagen Therapeutics, Inc.'s outside legal counsel? Latham & Watkins LLP 330 North Wabash Avenue, Suite 2800 Chicago, IL 60611 T: 312-876-7700 F: 312-993-9767 www.lw.com. Disclosure Law Group 655 West Broadway, Suite 870 San Diego, CA 92101 T: 619-272-7050 F: 619-330-3101 Vistagen is advancing therapeutics with the potential to be faster-act[6 VistaGen Therapeutics jobs. Apply to the latesEX-101.INS - XBRL INSTANCE DOCUMENT: Jun 30, 2020: 10-K: Annual r Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression and multiple CNS disorders. Vistagen's pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), …VistaGen Therapeutics. Phone: (650) 577-3606. Email: [email protected]. Company Profile VistaGen Therapeutics, Inc. Industry: Pharmaceuticals & Biotechnology Website: https://vistagen.com. PALISADE ...